VANGUARD GROUP INC 13D and 13G filings for Halozyme Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-27 09:33 am Sale | 2026-03-13 | 13G | HALOZYME THERAPEUTICS INC HALO | VANGUARD GROUP INC | 0 0.000% | -13,259,514 (Position Closed) | Filing |
| 2024-02-13 5:06 pm Sale | 2023-12-29 | 13G | HALOZYME THERAPEUTICS INC HALO | VANGUARD GROUP INC | 13,259,514 10.040% | -269,116 (-1.99%) | Filing |
| 2023-06-09 2:15 pm Purchase | 2023-05-31 | 13G | HALOZYME THERAPEUTICS INC HALO | VANGUARD GROUP INC | 13,528,630 10.270% | 224,783 (+1.69%) | Filing |
| 2023-02-09 11:22 am Sale | 2022-12-30 | 13G | HALOZYME THERAPEUTICS INC HALO | VANGUARD GROUP INC | 13,303,847 9.840% | -238,742 (-1.76%) | Filing |
| 2022-12-12 3:09 pm Purchase | 2022-11-30 | 13G | HALOZYME THERAPEUTICS INC HALO | VANGUARD GROUP INC | 13,542,589 10.020% | 46,676 (+0.35%) | Filing |
| 2022-02-10 08:17 am Purchase | 2021-12-31 | 13G | HALOZYME THERAPEUTICS INC HALO | VANGUARD GROUP INC | 13,495,913 9.590% | 346,210 (+2.63%) | Filing |